Showing results (11-20 of 16) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Chest|July 16, 2008
Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survivalRaymond L Benza, Robyn J Barst, Nazzareno Galie, et al.The European Respiratory Journal|August 9, 2019
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trialFernando Torres, Harrison Farber, Arsen Ristic, et al.Advances in Therapy|July 12, 2022
Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label ExtensionRogério Souza, Marion Delcroix, Nazzareno Galié, et al.Journal of the American College of Cardiology|June 25, 2003
Beraprost therapy for pulmonary arterial hypertensionRobyn J Barst, Michael McGoon, Vallerie McLaughlin, et al.Journal of the American College of Cardiology|April 23, 2003
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertensionNazzareno Galiè, Alan L Hinderliter, Adam Torbicki, et al.The Journal of Rheumatology|October 13, 2009
Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)Dinesh Khanna, Oliver Distler, Jerome Avouac, et al.Pageof 2